Kaitlyn Bader, Senior Editor

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

This Rosacea Awareness Month, take a look at previous coverage from 2024.

Miranti presented tips on handling denial hurdles and how to ensure patients receive access to the treatments they need.

From our April cover feature: Take an in-depth look at the basis of Valisure's benzene testing methods and practical recommendations for clinicians from Christopher Bunick, MD, PhD.

MoonLake’s sonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

This week’s collection of the latest dermatologic studies covers circulating tumor DNA in advanced cSCC, targeting IL-13 with tralokinumab in AD, a pediatric lymphoplasmocytic plaque case report, and skin of color reporting in randomized controlled trials focusing on SCC.

ICYMI, this week we had news about Ycanth's J-code launch, highlights from Diversity in Dermatology, bimekizumab's accepted sBLA for HS, and more.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

This week’s collection of the latest dermatologic studies covers topical permethrin 5% vs. benzyl benzoate 25% for scabies, the safety of omalizumab in CSU during pregnancy, symptoms of cognitive impairment in children with AD, and the ethics of cosmetic overtreatment.

The merger will focus on advancing Oruka’s portfolio of novel biologics for the treatment of chronic skin diseases.

Shah discusses the science behind his products, as well as the challenges he didn’t anticipate when launching Remedy.

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

Learn more about the in-depth topics covered in the March 2024 print issue of Dermatology Times.

Learn more about the in-depth topics covered in the March 2024 enhancing psoriasis management supplement of Dermatology Times.

Catch up on late-breaking research shared at the 2024 American Academy of Dermatology Annual Meeting.

Moving the Needle on Ethics includes articles and interviews featuring experts in aesthetics.

ICYMI, this week we had news about COVID-19 research and dermatology, Journey Medical's accepted NDA for DFD-29, late-breaking data on amlitelimab for AD, and more.

If approved, bimekizumab will be the first IL-17A and IL-17F inhibitor approved in Europe for hidradenitis suppurativa.

Two recently published studies evaluated the uses of and attitudes toward telehealth in dermatology after the COVID-19 pandemic.

On March 6, 2024, Valisure, an independent testing laboratory, found high levels of benzene when BPO products were incubated at 37°C, 50°C, and 70°C.

The anticipated PDUFA date is November 4, 2024.

This week’s collection of the latest dermatologic studies covers the relationship between vitamin D receptor expression and cutaneous melanoma outcomes, efficacy of intravenous immunoglobulin in adults with treatment-resistant eosinophilic fasciitis, high dose oral isotretinoin versus low dose for cutaneous and genital warts, and the loss of integrity in the dermal-epidermal junction and hemidesmosomes during skin aging.

Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.

Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.

The Bristol Myers Squibb-hosted event brought together a panel of leading women in dermatology to discuss the challenges they’ve faced and how women can support each other.

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.

Christopher Bunick, MD, PhD, presented updates and new data on the recent news of benzene found in benzoyl peroxide products.

Naiem Issa, MD, PhD, emphasized the importance of increased awareness regarding antibiotic stewardship among dermatologists, as well as the recently updated acne guidelines.

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.